Haleos Labs Ltd
Haleos Labs Ltd (HALEOSLABS) last reported results for the quarter ended Jun 2026, with sales of ₹72.94 crore and net profit of ₹1.84 crore. The stock last traded at ₹1,586, a market capitalisation of ₹480 crore, on a P/E of 30.3. Over the past 52 weeks the stock has ranged between ₹1,091 and ₹1,778. Figures are as of 6 Oct 2026 and are not real time.
Haleos Labs Ltd share price and key metrics
- Current price
- ₹1,586
- Market cap
- ₹480 cr
- Stock P/E
- 30.3
- Book value
- ₹706
- ROE
- 8.44%
- ROCE
- 9.91%
- Dividend yield
- 0.10%
- 52w high / low
- 1778/1091
Metrics as of 6 Oct 2026. Not real time.
Track Haleos Labs Ltd
Cruxal reads every Haleos Labs Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Haleos Labs Ltd growth and returns
- 10 Years
- %
- 5 Years
- 5%
- 3 Years
- 2%
- TTM
- -3%
- 10 Years
- %
- 5 Years
- 5%
- 3 Years
- 20%
- TTM
- -8%
- 10 Years
- %
- 5 Years
- 15%
- 3 Years
- 44%
- 1 Year
- 34%
- 10 Years
- %
- 5 Years
- 8%
- 3 Years
- 8%
- Last Year
- 8%
Haleos Labs Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹72.94 cr, down 11.6% from ₹82.5 cr a year earlier. Net profit was ₹1.84 cr, down 58.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 78.46 | 84.6 | 89.11 | 82.5 | 81.37 | 94.78 | 75.14 | 72.94 |
| Expenses | 69.89 | 71.85 | 81.69 | 70.79 | 67.79 | 80.73 | 70.98 | 63.82 |
| Operating profit | 8.57 | 12.75 | 7.42 | 11.71 | 13.58 | 14.05 | 4.16 | 9.12 |
| OPM % | 10.92% | 15.07% | 8.33% | 14.19% | 16.69% | 14.82% | 5.54% | 12.50% |
| Other income | 2.04 | 0.06 | 2.34 | 1 | 0.42 | 0.18 | 2.01 | 0.46 |
| Interest | 2.14 | 2.14 | 2.03 | 1.87 | 1.62 | 1.54 | 1.42 | 1.9 |
| Depreciation | 3.76 | 3.76 | 3.8 | 3.82 | 3.89 | 3.91 | 3.85 | 4.24 |
| Profit before tax | 4.71 | 6.91 | 3.93 | 7.02 | 8.49 | 8.78 | 0.9 | 3.44 |
| Tax % | 29.72% | 29.81% | 11.45% | 37.61% | 24.38% | 24.26% | 62.22% | 46.51% |
| Net profit | 3.3 | 4.86 | 3.48 | 4.39 | 6.42 | 6.65 | 0.35 | 1.84 |
| EPS (₹) | 15.45 | 18.09 | 9.82 | 13.76 | 20.18 | 21.90 | 1.46 | 8.77 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Haleos Labs Ltd annual results
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 378 | 261 | 266 | 350 | 316 | 306 | 345 | 334 | 324 |
| Operating profit | 35 | 25 | 30 | 35 | 29 | 31 | 45 | 45 | 41 |
| OPM % | 9% | 10% | 11% | 10% | 9% | 10% | 13% | 13% | 13% |
| Net profit | 18 | 10 | 14 | 25 | 11 | 6 | 19 | 18 | 15 |
| EPS (₹) | 59.04 | 33.67 | 44.85 | 83.75 | 37.91 | 30.07 | 66.52 | 57.26 | 52.31 |
TTM is the trailing twelve months to the most recent quarter.
Haleos Labs Ltd balance sheet
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 103 | 113 | 126 | 149 | 166 | 174 | 194 | 211 |
| Borrowings | 47 | 65 | 65 | 80 | 100 | 101 | 86 | 111 |
| Other liabilities | 116 | 72 | 108 | 125 | 126 | 114 | 107 | 130 |
| Total liabilities | 270 | 253 | 302 | 357 | 395 | 391 | 390 | 454 |
| Fixed assets | 118 | 124 | 130 | 142 | 228 | 223 | 232 | 268 |
| CWIP | 3 | 16 | 38 | 51 | 1 | 6 | 0 | 10 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 148 | 113 | 134 | 164 | 166 | 162 | 158 | 176 |
| Total assets | 270 | 253 | 302 | 357 | 395 | 391 | 390 | 454 |
As reported by the company. Total assets equal total liabilities by construction.
Haleos Labs Ltd cash flow
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 30 | 15 | 35 | -11 | 15 | 24 | 34 | 37 |
| Cash from investing | -44 | -27 | -26 | -7 | -31 | -18 | -15 | -58 |
| Cash from financing | 15 | 12 | -3 | 11 | 17 | -7 | -19 | 21 |
| Net cash flow | 1 | -0 | 6 | -8 | 0 | -1 | -0 | 1 |
| Free cash flow | 6 | -9 | -0 | -53 | -28 | 4 | 19 | -21 |
| CFO / operating profit | 105% | 69% | 133% | -10% | 62% | 88% | 94% | 98% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Haleos Labs Ltd operating ratios
| Per year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | — | 12% | 13% | 12% | 8% | 7% | 12% | 10% |
| Debtor days | 40 | 30 | 47 | 35 | 53 | 61 | 73 | 67 |
| Inventory days | 116 | 149 | 164 | 159 | 184 | 196 | 160 | 210 |
| Days payable | 140 | 101 | 163 | 146 | 127 | 143 | 126 | 162 |
| Cash conversion cycle | 16 | 78 | 48 | 48 | 110 | 115 | 106 | 116 |
| Working capital days | 14 | 18 | 2 | 17 | 24 | 11 | 7 | 5 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Haleos Labs Ltd shareholding pattern
Promoters held 72.10% at Jun 2026, up from 71.40% at Jun 2025. FIIs 0.00% and DIIs 0.31%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 71.40% | 71.40% | 71.40% | 71.40% | 71.40% | 71.79% | 72.10% | 72.10% |
| FIIs | 0.02% | 0.00% | 0.00% | 0.03% | 0.00% | 0.00% | 0.00% | 0.00% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.03% | 0.29% | 0.30% | 0.31% |
| Public | 28.57% | 28.59% | 28.60% | 28.56% | 28.57% | 27.91% | 27.59% | 27.58% |
| No. of shareholders | 7,849 | 7,626 | 7,479 | 7,412 | 7,521 | 7,125 | 6,937 | 6,859 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Haleos Labs Ltd corporate filings
- Scrutinizer's Report confirms passing of all resolutions at Haleos Labs' 20th AGM with majority votes, highlighting strong shareholder support for key proposals including reappointment of directors and remuneration approvals.AGM/EGMmedium impact
Cruxal's analysis: The detailed scrutinizer's report (pages 11-19) confirms that all resolutions, including…
Read the full analysis - Haleos Labs Limited Conducts 20th AGM; No Financial Results or Strategic Announcements DisclosedAGM/EGMlow impact
Cruxal's analysis: Haleos Labs Limited held its 20th Annual General Meeting on September 30, 2026, via video…
Read the full analysis - Intimation of Closure of Trading Window.Insider Trading / SASTlow impact
- Haleos Labs Ltd provides update on material subsidiary regarding USFDA statusCompany Updatelow impact
Cruxal's analysis: Haleos Labs Ltd has issued a formal update concerning its material subsidiary in relation…
Read the full analysis - Haleos Labs Limited Announces 20th Annual General Meeting and Dividend Record DateCompany Updatelow impact
Cruxal's analysis: Haleos Labs Limited has scheduled its 20th Annual General Meeting for September 30, 2026…
Read the full analysis - Haleos Labs Limited Announces 20th Annual General Meeting (AGM) for September 30, 2026Company Updatelow impact
Cruxal's analysis: Haleos Labs Limited has issued a formal notice for its 20th Annual General Meeting (AGM)…
Read the full analysis - Haleos Labs Limited Announces 20th AGM with Dividend Declaration and Managerial Remuneration RevisionAGM/EGMlow impact
Cruxal's analysis: Haleos Labs Limited has scheduled its 20th Annual General Meeting for September 30, 2026…
Read the full analysis - Haleos Labs Ltd files Annual Report for the financial year ended 31st March 2026Otherslow impact
Cruxal's analysis: Haleos Labs Ltd has submitted its Annual Report for the fiscal year ended 31st March 2026…
Read the full analysis - Haleos Labs Limited fixes September 23, 2026 as Record Date for Dividend and 20th AGMCorp. Actionlow impact
Cruxal's analysis: Haleos Labs Limited has officially announced September 23, 2026, as the record date to…
Read the full analysis - Haleos Labs Limited schedules 20th Annual General Meeting for September 30, 2026Company Updatelow impact
Cruxal's analysis: Haleos Labs Limited has formally announced the schedule for its 20th Annual General…
Read the full analysis - Haleos Labs Limited shareholders reject managerial remuneration proposal in recent postal ballotAGM/EGMmedium impact
Cruxal's analysis: Haleos Labs Limited announced the results of its recent postal ballot, where shareholders…
Read the full analysis - Haleos Labs Ltd issues routine communication to shareholders regarding TDS on dividend paymentsCompany Updatelow impact
Cruxal's analysis: Haleos Labs Ltd has issued a standard communication to its shareholders regarding Tax…
Read the full analysis - Haleos Labs Limited Reports Q1 FY2027 Financial Results with Revenue of 72.94 croreCompany Updatelow impact
Cruxal's analysis: Haleos Labs Limited (formerly SMS Lifesciences India Limited) has published its financial…
Read the full analysis - Haleos Labs Ltd announces appointment of Cost Auditor and Nominee Director for subsidiary Mahi Drugs Private LimitedCompany Updatelow impact
Cruxal's analysis: Haleos Labs Ltd has appointed a Cost Auditor for the financial year 2026-27 and…
Read the full analysis - Haleos Labs Ltd announces reappointment of Independent Directors for a second 5-year termCompany Updatelow impact
Cruxal's analysis: Haleos Labs Ltd has proposed the reappointment of Dr. Mannam Malakondaiah and Dr…
Read the full analysis - Haleos Labs Limited Reports Q1 FY27 Financial Results and Announces 20th AGMBoard Meetingmedium impact
Cruxal's analysis: Haleos Labs Limited (formerly SMS Lifesciences India Limited) reported standalone revenue…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.